3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
2
Status
Active not recruiting
4
Terminated
3
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
4
Study Type
Interventional
4
Sponsor
Cancer Type
Thoracic
3
Tumor-Agnostic
1
Conditions
Carcinoma, Non-Small-Cell Lung
41
Lung Neoplasms
11
Neoplasm Metastasis
5
Carcinoma
4
Neoplasms
3
Brain Neoplasms
3
Stomach Neoplasms
2
NSCLC
2
Multiple Myeloma
2
Lymphoma
2
Hematologic Neoplasms
2
Colorectal Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stage II-IIIB Non-small Cell Lung Carcinoma
1
Stage IB-IIIA Non-small Cell Lung Carcinoma
1
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Non-small Cell Carcinoma
1
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)
1
Melanoma
1
Head and Neck Neoplasms
1
Glioma
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Interventions
Cisplatin
10
pembrolizumab
8
Carboplatin
8
Paclitaxel
6
durvalumab
5
Pemetrexed
5
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
5
osimertinib
4
Specimen Handling
4
Magnetic Resonance Spectroscopy
4
Taxes
3
Nivolumab
3
Gemcitabine
3
Docetaxel
3
Bevacizumab
3
cabozantinib
2
atezolizumab
2
Sunitinib
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
Radiation
2
Platinum
2
Immunoglobulin G
2
Disulfides
2
CP protocol
2
Biopsy
2
1,2-diaminocyclohexaneplatinum II citrate
2
trifluridine tipiracil drug combination
1
tremelimumab
1
relatlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Active not recruiting
×
Carcinoma
×
osimertinib
×
Clear all
NCT03778229
2026-04-23
SAVANNAH
AstraZeneca
Phase 2
Active not recruiting
367 enrolled
32 charts
NCT05261399
2026-04-06
SAFFRON
AstraZeneca
Phase 3
Active not recruiting
345 enrolled
NCT04606771
2026-02-27
CoC
AstraZeneca
Phase 2
Active not recruiting
30 enrolled
20 charts
NCT04035486
2025-10-10
FLAURA2
AstraZeneca
Phase 3
Active not recruiting
587 enrolled
44 charts
1 FDA